Last reviewed · How we verify
Pathocil (DICLOXACILLIN)
Pathocil (Dicloxacillin) is a penicillin-class antibacterial drug developed by Wyeth Ayerst, now owned by the same company. It targets the muscarinic acetylcholine receptor M1 and is used to treat various bacterial infections, including acute bacterial sinusitis, osteomyelitis, and staphylococcal pneumonia. Pathocil is a small molecule with a half-life of 0.88 hours and bioavailability of 68%. It is off-patent and has multiple generic manufacturers. Key safety considerations include its potential for allergic reactions and interactions with other medications.
At a glance
| Generic name | DICLOXACILLIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class Antibacterial |
| Target | Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1968 |
Approved indications
- Acute bacterial sinusitis
- Continuation Therapy for Acute Osteomyelitis
- Continuation Therapy for Chronic Osteomyelitis
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Staphylococcal pneumonia
- Staphylococcus Aureus Bronchitis
Common side effects
- Allergic reactions
- Urticaria
- Pruritus
- Angioneurotic edema
- Laryngospasm
- Bronchospasm
- Hypotension
- Vascular collapse
- Death
- Nausea
- Vomiting
- Diarrhea
Drug interactions
- warfarin
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Antibiotic Concentrations Among Critically Ill Patients
- Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
- Oral-only Antibiotics for Bone and Joint Infections in Children (PHASE4)
- Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture (NA)
- Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA (NA)
- Individualized Treatment of Acute Achilles Tendon Rupture (NA)
- Intramedullary Nailing vs External Ring Fixation for the Treatment of Tibial Shaft Fractures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pathocil CI brief — competitive landscape report
- Pathocil updates RSS · CI watch RSS
- Pfizer portfolio CI